The LIMS1 (LIM and Senescent Cell Antigen-Like Domains 1) protein, also known as PINCH1. is a member of the LIM domain-containing protein family. It functions primarily as a scaffolding protein in integrin-mediated signaling pathways, playing a critical role in cell-matrix adhesion, cytoskeletal organization, and cell migration. LIMS1 interacts with integrin-linked kinase (ILK) and Parvin to form the IPP (ILK-PINCH-Parvin) complex, which regulates cellular processes such as survival, proliferation, and differentiation. Its involvement in these pathways links LIMS1 to various physiological and pathological conditions, including cancer progression, tissue fibrosis, and cardiovascular diseases.
Antibodies targeting LIMS1 are essential tools for studying its expression, localization, and functional interactions. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate LIMS1's role in cellular signaling and disease mechanisms. For instance, elevated LIMS1 levels have been observed in certain cancers (e.g., prostate and breast cancer), where it may promote tumor invasion and metastasis. Conversely, reduced expression has been associated with neurodegenerative disorders. Researchers also utilize LIMS1 antibodies to explore its potential as a biomarker or therapeutic target. These antibodies must be validated for specificity, as LIMS1 shares structural homology with its paralog, PINCH2 (LIMS2). Understanding LIMS1's context-dependent roles continues to be a focus in cell biology and translational research.